The Japanese experience with biologic therapies for rheumatoid arthritis

Nature Reviews Rheumatology

Volumn 6, Issue 11, 2010, Pages 644-652

  Takeuchi, Tsutomu ^a   Kameda, Hideto ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; BUCILLAMINE; COTRIMOXAZOLE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; ISONIAZID; LEFLUNOMIDE; METHOTREXATE; PLACEBO; RITUXIMAB; TACROLIMUS; TOCILIZUMAB;

ACUTE RESPIRATORY FAILURE; ARTHROPATHY; BACTERIAL PNEUMONIA; CLINICAL TRIAL; DRUG ABSORPTION; DRUG APPROVAL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ETHNIC DIFFERENCE; HUMAN; INFECTION; INFUSION REACTION; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; JAPAN; LOW DRUG DOSE; MONOTHERAPY; NONHUMAN; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECEPTOR BLOCKING; RECOMMENDED DRUG DOSE; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; TUBERCULOSIS;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL THERAPY; HUMANS; IMMUNOGLOBULIN G; JAPAN; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME;

EID: 78049508184     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2010.154     Document Type: Review

References (66)

1. Khan, M. A. HLA-B27 and its subtypes in world populations. Curr. Opin. Rheumatol. 7, 263-269 (1995).
2. Takeuchi, T. et al. Postmarketing surveillance of the safety profile of infliximab in 5, 000 Japanese patients with rheumatoid arthritis. Ann. Rheum. Dis. 67, 189-194 (2008).
3. Health white paper [Japanese]. Japanese Ministry of Health [online], http://www.mhlw.go. jp/wp/hakusyo/kousei/09-02/kousei-data/pdfNFindex.html (2010).
4. Abe, T. et al. A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis. J. Rheumatol. 33, 37-44 (2006).
5. Koike, T. et al. Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. J. Rheumatol. 36, 898-906 (2009).
6. Miyasaka, N.; CHANGE Study Investigators. Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. Mod. Rheumatol. 18, 252-262 (2008).
7. Sokka, T., Envalds, M. & Pincus, T. Treatment of rheumatoid arthritis: a global perspective on the use of antirheumatic drugs. Mod. Rheumatol. 18, 228-239 (2008).
8. Kameda, H. et al. Factors predicting response to a low-dose methotrexate therapy in patients with rheumatoid arthritis: A better response in male patients. Mod. Rheumtol 14, 442-446 (2004).
9. Smolen, J. S. et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann. Rheum. Dis. 69, 631-637 (2010).
10. visser, K. & van der Heijde, D. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann. Rheum. Dis. 68, 1094-1099 (2009).
11. Sekiguchi, N., Kameda, H., Amano, K. & Takeuchi, T. Efficacy and safety of bucillamine, a D-penicillamine analogue, in patients with active rheumatoid arthritis. Mod. Rheumatol. 16, 85-91 (2006).
12. Ichikawa, Y. et al. Therapeutic effects of the combination of methotrexate and bucillamine in early rheumatoid arthritis: a multicenter, doubleblind, randomized controlled study. Mod. Rheumatol. 15, 323-328 (2005).
13. Osiri, M, et al. Leflunomide for the treatment of rheumatoid arthritis: a systematic review and meta-analysis. J. Rheumatol. 30, 1182-1190 (2003).
14. Sawada, T. et al. Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis. Rheumatology (Oxford) 48, 1069-1072 (2009).
15. Sato, T. et al. Factors associated with fatal outcome of leflunomide-induced lung injury in Japanese patients with rheumatoid arthritis. Rheumatology (Oxford) 48, 1265-1268 (2009).
16. Safety information of leflunomide in Japan [Japanese]. Sanofi-Aventis [online], http://safety.sanofi-aventis.co.jp/arava/aravap/index.html (2010).
17. Suzuki, K. et al. Single center prospective study of tacrolimus efficacy and safety in treatment of rheumatoid arthritis. Rheumatol. Int. 29, 431-436 (2009).
18. Takeuchi, T., Kawai, S., Yamamoto, K. & Miyasaka, N. Post-marketing surveillance of the safety and effectiveness of tacrolimus in 3, 267 Japanese patients with rheumatoid arthritis. Ann. Rheum. Dis. 69 (Suppl. 3), 219 (2010).
19. Nishimoto, N. et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 50, 1761-1769 (2004).
20. Phase II dose-finding clinical trials for abatacept [Japanese]. Enbrel [online], http://www.enbrel.jp/member/data/result.html (2010).
21. Takeuchi, T., Abe, T., Yamamoto, A. & Miyasaka, N. New biologics for rheumatoid arthritis in Japan; A multi-center randomized double-blind, controlled, dose-response study of abatacept (BMS-188667) in Japanese active rheumatoid arthritis (RA) patients with an inadequate response to methotrexate. Mod. Rheumatol. 19, S32 (2009).
22. Takeuchi, T., Miyasaka, N., Inoue, K., Abe, T. & Koike, T. Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study. Mod. Rheumatol. 19, 478-487 (2009).
23. Kameda, H. et al. Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: A randomized trial. Mod. Rheum. doi:10.1007/s10165-010-0324-4.
24. Yamanaka, H. et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM). Mod. Rheumatol. 17, 28-32 (2007).
25. Tanaka, Y. et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: One-year clinical and radiographic outcomes (RECONFIRM-II). Mod. Rheumatol. 18, 146-152 (2008).
26. Takeuchi, T. et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year outcome of joint destruction (RECONFIRM-2J). Mod. Rheumatol. 18, 447-454 (2008).
27. Lipsky, P. E. et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N. Engl. J. Med. 343, 1594-1602 (2000).
28. Kameda, H. et al. Etanercept (ETN) plus methotrexate (MTX) combination therapy resulted in a better outcome in joint damage and physical function than ETN monotherapy even in patients with active rheumatoid arthritis despite MTX treatment: 52-week results from the JESMR study. Ann. Rheum. Dis. 68 (Suppl. 3), 121 (2009).
29. Kawai, S. et al. Comparability of etanercept pharmacokinetics in healthy Japanese and American subjects. J. Clin. Pharmacol. 46, 418-423 (2006).
30. van de Putte, L. B. et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann. Rheum. Dis. 63, 508-516 (2004).
31. Nishimoto, N. et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod. Rheumatol. 19, 12-19 (2009).
32. Nishimoto, N. et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann. Rheum. Dis. 66, 1162-1167 (2007).
33. Nishimoto, N. et al. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann. Rheum. Dis. 68, 1580-1584 (2009).
34. Yamanaka, H. et al. Efficacy of tocilizumab in rheumatoid arthritis patients with daily clinical practice in Japan: Results from a retorspective study (REACTION). Ann. Rheum. Dis. 69 (Suppl. 3), 547 (2010).
35. Miyasaka, N., Takeuchi, T. & Eguchi, K. Proposed [corrected] Japanese guidelines for the use of infliximab for rheumatoid arthritis. Mod. Rheumatol. 15, 4-8 (2005).
36. Miyasaka, N., Takeuchi, T. & Eguchi, K. Guidelines for the proper use of etanercept in Japan. Mod. Rheumatol. 16, 63-67 (2006).
37. Koike, R., Takeuchi, T., Eguchi, K. & Miyasaka, N. Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. Mod. Rheumatol. 17, 451-458 (2007).
38. Koike, R. et al. Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis. Mod. Rheumatol. 19, 351-357 (2009).
39. Guidelines for adalimumab [Japanese]. Japan College of Rheumatology [online], http://www.ryumachi-jp.com/info/080724-ADA.html (2008).
40. Keane, J. et al. Tuberculosis associated with infliximab, a tumor necrosis factor alphaneutralizing agent. N. Engl. J. Med. 345, 1098-1104 (2001).
41. Arthritis advisory committee. Safety Update on TNF-α antagonists: infliximab and etanercept. FDA [online], http://www.fda.gov/OHRMS/DOCKETS/ac/01/ briefing/3779b2-01-1-CBER. briefing.safety.pdf (2001).
42. Komano, Y. et al. Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients. Arthritis Rheum. 61, 305-312 (2009).
43. Tokuda, H. et al. Clinical and radiological features of Pneumocystis pneumonia in patients with rheumatoid arthritis, in comparison with methotrexate pneumonitis and Pneumocystis pneumonia in acquired immunodeficiency syndrome: a multicenter study. Intern. Med. 47, 915-923 (2008).
44. Saijo, S. et al. Dectin-1 is required for host defense against Pneumocystis carinii but not against Candida albicans. Nat. Immunol. 8, 39-46 (2007).
45. Steele, C. et al. Alveolar macrophage-mediated killing of Pneumocystis carinii f. sp. muris involves molecular recognition by the Dectin-1 β-glucan receptor. J. Exp. Med. 198, 1677-1688 (2003).
46. Hahn, P. Y. et al. Pneumocystis carinii cell wall β-glucan induces release of macrophage inflammatory protein-2 from alveolar epithelial cells via a lactosylceramide-mediated mechanism. J. Biol. Chem. 278, 2043-2050 (2003).
47. Tasaka, S. et al. Serum indicators for the diagnosis of pneumocystis pneumonia. Chest 131, 1173-1180 (2007).
48. Ohosone, Y. et al. Clinical characteristics of patients with rheumatoid arthritis and methotrexate induced pneumonitis. J. Rheumatol. 24, 2299-2303 (1997).
49. Shidara, K. et al. Incidence of and risk factors for interstitial pneumonia in patients with rheumatoid arthritis in a large Japanese observational cohort, IORRA. Mod. Rheumatol. 20, 280-286 (2010).
50. Kameda, H. & Takeuchi, T. Recent advances in the treatment of interstitial lung disease in patients with polymyositis/dermatomyositis. Endocr. Metab. Immune Disord. Drug Targets 6, 409-415 (2006).
51. Azuma, A., Hagiwara, K. & Kudoh, S. Basis of acute exacerbation of idiopathic pulmonary fibrosis in Japanese patients. Am. J. Respir. Crit. Care Med. 177, 1397-1398 (2008).
52. Kudoh, S. et al. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am. J. Respir. Crit. Care Med. 177, 1348-1357 (2008).
53. Abe, T. & Takeuchi, T. The other side of TNF-targeted therapy of patients with rheumatoid arthritis. Curr. Rheumatol. Rep. 3, 1-2 (2001).
54. Quinn, M. A. et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelvemonth randomized, double-blind, placebocontrolled trial. Arthritis Rheum. 52, 27-35 (2005).
55. van der Kooij, S. M. et al. Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis. Ann. Rheum. Dis. 68, 914-921 (2009).
56. Tanaka, Y. et al. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann. Rheum. Dis. 69, 1286-1291 (2010).
57. Radovits, B. J. et al. Influence of age on the outcome of antitumour necrosis factor alpha therapy in rheumatoid arthritis. Ann. Rheum. Dis. 68, 1470-1473 (2009).
58. Tutuncu, Z. et al. Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents. Arthritis Rheum. 52, 2693-2696 (2005).
59. Canete, J. D. et al. Influence of variants of Fcγ receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor α therapy in rheumatoid arthritis. Ann. Rheum. Dis. 68, 1547-1552 (2009).
60. Sekiguchi, N. et al. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-α monoclonal antibody, infliximab. Rheumatology (Oxford) 47, 780-788 (2008).
61. Tanino, M. et al. Prediction of efficacy of anti-TNF biologic agent, infliximab, for rheumatoid arthritis patients using a comprehensive transcriptome analysis of white blood cells. Biochem. Biophys. Res. Commun. 387, 261-265 (2009).
62. Sugihara, M. et al. Effects of infliximab therapy on gene expression levels of tumor necrosis factor α, tristetraprolin, T cell intracellular antigen 1, and Hu antigen R. in patients with rheumatoid arthritis. Arthritis Rheum. 56, 2160-2169 (2007).
63. Tsuzaka, K., Itami, Y., Takeuchi, T., Shinozaki, N. & Morishita, T. ADAMTS5 is a biomarker for prediction of the response to infliximab in patients with rheumatoid arthritis. J. Rheumatol. 37, 1454-1460 (2010).
64. Kastbom, A. et al. Fcγ receptor type IIIA genotype and response to tumor necrosis factor α-blocking agents in patients with rheumatoid arthritis. Arthritis Rheum. 56, 448-452 (2007).
65. Pavy, S. et al. Tumour necrosis factorα-308G->A polymorphism is not associated with response to TNFα blockers in Caucasian patients with rheumatoid arthritis: systematic review and meta-analysis. Ann. Rheum. Dis. 69, 1022-1028 (2010).
66. Hughes, L. B. et al. Genetic risk factors for infection in patients with early rheumatoid arthritis. Genes Immun. 5, 641-647 (2004).